Abstract Search

ea0098c31 | Clinical – Nuclear Medicine/Interventional Radiology/Imaging | NANETS2023

High-specific-activity iodine-131-meta-iodo-benzylguanidine for the treatment of advanced pheochromocytoma and paraganglioma: a real-world study

Al-Ward Ruaa , Balderrama Brondan Vania , Sawani Sahar , Bassett Roland , Xu Guofan , Waguespack Steven G. , Varghese Jeena , Amir Habra Mouhammed , Lu Yang , Jimenez Camilo

Background: Metastatic pheochromocytomas and paragangliomas are rare neuroendocrine tumors with limited treatment options. We studied the efficacy and safety of off-label High-Specific-Activity I-131-meta-iodobenzylguanidine (HSA-I-131-MIBG) in routine clinical practice. Methods: This is a retrospective cohort study. The primary endpoint is objective response rate (ORR) as per RECIST v1.1. Secondary endpoints are blood pressure control, safety, overall a...

0 shares

Endocrine Abstracts

High-specific-activity iodine-131-meta-iodo-benzylguanidine for the treatment of advanced pheochromocytoma and paraganglioma: a real-world study

BiosciAbstracts